瑞康医药(002589) - 2021 Q1 - 季度财报

Financial Performance - The company's operating revenue for Q1 2021 was CNY 5,764,538,064.30, representing a slight increase of 0.02% compared to the same period last year[10]. - Net profit attributable to shareholders decreased by 13.03% to CNY 81,657,820.38, down from CNY 95,605,125.24 in the previous year[10]. - The basic earnings per share decreased by 16.67% to CNY 0.05, down from CNY 0.06 in the previous year[10]. - The company reported a significant decrease of 191.77% in net profit after deducting non-recurring gains and losses, resulting in a loss of CNY 68,171,798.57[10]. - Net profit for Q1 2021 was CNY 167,031,404.28, compared to CNY 158,158,703.80 in the same period last year, reflecting an increase of 5.5%[41]. - The company's operating revenue for the current period is ¥2,182,037,786.21, a decrease of 9.5% compared to ¥2,411,462,489.00 in the previous period[44]. - Operating profit for the current period is ¥31,061,149.95, down from ¥35,251,966.07, reflecting a decline of 6.8%[45]. - Net profit for the current period is ¥33,332,503.95, slightly up from ¥33,066,666.60, indicating a growth of 0.8%[46]. Cash Flow - The net cash flow from operating activities was CNY 124,685,642.80, a decline of 16.04% compared to CNY 160,958,588.20 in the same quarter last year[10]. - Cash received from operating activities increased by 34.15% to RMB 901.38 million, driven by higher cash inflows from asset securitization[19]. - Cash received from the disposal of subsidiaries decreased by 77.65% to RMB 26.28 million, indicating fewer disposals compared to the previous year[19]. - Cash inflows from short-term borrowings decreased by 44.95% to RMB 2,280.36 million, reflecting a reduction in new borrowings[19]. - Cash outflows for financing activities increased by 90.83% to RMB 571.66 million, primarily due to higher bank acceptance deposits returned[19]. - The net cash flow from operating activities is ¥124,685,642.80, down from ¥148,508,228.94, a decrease of 16.0%[49]. - Total cash inflow from operating activities was 2,936,292,106.06, up from 2,518,156,199.27, representing an increase of approximately 16.6%[52]. - The net cash flow from financing activities was 444,142,002.47, a decrease from 554,291,108.03 in the previous period[53]. Assets and Liabilities - Total assets at the end of the reporting period were CNY 32,364,585,947.66, reflecting a 0.75% increase from CNY 31,290,194,324 at the end of the previous year[10]. - The company's total assets reached CNY 24,632,768,860.96, up from CNY 23,094,268,728.49, marking a growth of 6.7%[37]. - The total liabilities of the company were CNY 21.80 billion, compared to CNY 21.61 billion at the end of 2020, with current liabilities accounting for CNY 21.46 billion[33][34]. - The company's current assets totaled CNY 26.46 billion, slightly down from CNY 26.55 billion at the end of 2020, with cash and cash equivalents at CNY 5.99 billion, up from CNY 5.75 billion[30][31]. - The company reported a decrease in short-term borrowings to CNY 8.82 billion from CNY 9.51 billion, while accounts payable remained relatively stable at CNY 4.51 billion[32][33]. Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 1,504,710,471[14]. - The top shareholder, Zhang Renhua, holds 19.13% of the shares, amounting to 287,866,059 shares[14]. - The equity attributable to shareholders of the parent company was CNY 7.51 billion, a slight increase from CNY 7.47 billion at the end of 2020[34]. Investment and Expenses - Research and development expenses decreased by 35.34% to RMB 1.74 million, due to reduced investment in medical insurance and cost control software compared to the previous year[18]. - Investment income fell by 41.88% to RMB 109.39 million, primarily due to reduced investment gains from divestitures[18]. - The company incurred financial expenses of ¥87,580,171.92, an increase from ¥64,403,865.08, reflecting a rise of 36.0%[44]. - The company paid out ¥230,013,426.03 in dividends and interest, up from ¥152,307,430.97, representing an increase of 51.1%[50]. - The company reported an investment income of CNY 109,392,123.48, down from CNY 188,202,987.52, a decrease of 41.8%[40]. Other Information - The company did not engage in derivative investments or entrusted financial management during the reporting period[23][24]. - There were no significant changes in the company's major contracts or non-operating fund occupation by controlling shareholders during the reporting period[25][26]. - The company has not reported any major research, communication, or interview activities during the reporting period[26][27]. - The company has not provided any guidance on expected operating performance for the first half of 2021[23].